{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:26:49Z","timestamp":1762079209866},"reference-count":92,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2010,9,2]],"date-time":"2010-09-02T00:00:00Z","timestamp":1283385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Psoriasis is a chronic, systemic inflammatory disorder manifesting primarily in skin and potentially in joints, frequently necessitating treatment with conventional systemic therapies, phototherapy or biological agents. Patients with moderate to severe disease suffer a diminished quality of life, experience significant comorbidities and have a higher mortality. Although traditional treatments are effective in the short\u2010term, their use is often limited by concerns over long\u2010term toxicity, including end\u2010organ damage and risk of malignancy. Combination therapy is a commonly used approach and is often more effective than any single agent. Lower doses of two treatments in combination can also minimize potential side effects from a single agent at higher doses. Etanercept is a recombinant human tumour necrosis factor (TNF)\u03b1 receptor (p75) protein fused with the Fc portion of IgG1 that binds to TNF\u03b1. This article reviews the evidence on the efficacy and safety of etanercept in combination with methotrexate, acitretin, narrowband UVB and cyclosporin. The largest body of evidence assesses the combination with methotrexate, although evidence is available for the other combinations. Data suggest that although highly effective as monotherapy, etanercept in combination with a conventional systemic agent can enhance efficacy and allow drug sparing. Potentially, the combination may also result in faster treatment responses and permit safe transitioning from one systemic agent to another. Evidence to date suggests that these benefits can be achieved without significant additional toxicity, although long\u2010term data on the efficacy and safety of the combination in psoriatic populations is limited and further evaluation is warranted.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2010.03613.x","type":"journal-article","created":{"date-parts":[[2010,3,24]],"date-time":"2010-03-24T04:01:08Z","timestamp":1269403268000},"page":"1135-1143","source":"Crossref","is-referenced-by-count":26,"title":["Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence"],"prefix":"10.1111","volume":"24","author":[{"given":"PA","family":"Foley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Quirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JR","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Dolianitis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SP","family":"Hack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Thirunavukkarasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AJ","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,9,2]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.040"},{"key":"e_1_2_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.039"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630701364768"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283031c99"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.11.1425"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.14.1735"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700410"},{"key":"e_1_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.12.1493"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.08.040"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629010-00004"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2007.11.006"},{"key":"e_1_2_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61129-5"},{"key":"e_1_2_4_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08564.x"},{"key":"e_1_2_4_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08315.x"},{"key":"e_1_2_4_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021359"},{"key":"e_1_2_4_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08284.x"},{"key":"e_1_2_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(88)70198-X"},{"key":"e_1_2_4_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2007.02226.x"},{"key":"e_1_2_4_20_2","first-page":"159","article-title":"Effectiveness and side effects of UVB\u2010phototherapy, dithranol inpatient therapy and a care instruction programme of short contact dithranol in moderate to severe psoriasis","volume":"14","author":"Sminkels OQ","year":"2004","journal-title":"Eur J Dermatol"},{"key":"e_1_2_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(03)01144-7"},{"key":"e_1_2_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2002.12.002"},{"key":"e_1_2_4_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2001.00829.x"},{"key":"e_1_2_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.04.031"},{"key":"e_1_2_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)80148-4"},{"key":"e_1_2_4_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08512.x"},{"key":"e_1_2_4_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-9740.2006.05679.x"},{"key":"e_1_2_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.11.1043"},{"key":"e_1_2_4_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2008.03419.x"},{"key":"e_1_2_4_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08865.x"},{"key":"e_1_2_4_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.09019.x"},{"key":"e_1_2_4_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030409"},{"key":"e_1_2_4_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06688.x"},{"key":"e_1_2_4_34_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630500472838"},{"key":"e_1_2_4_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08771.x"},{"key":"e_1_2_4_36_2","volume-title":"Etanercept 50\u2003mg Once Weekly Sustains Safety and Efficacy for up to 96\u2003Weeks in Plaque Psoriasis Patients","author":"Elewski B","year":"2006"},{"key":"e_1_2_4_37_2","volume-title":"Assessment of the Long\u2010Term Safety of Etanercept for the Treatment of Psoriasis in an Adult Canadian Population","author":"Papp K","year":"2008"},{"key":"e_1_2_4_38_2","doi-asserted-by":"publisher","DOI":"10.1586\/17469872.3.6.657"},{"key":"e_1_2_4_39_2","first-page":"683","article-title":"Etanercept in the treatment and retreatment of psoriasis in daily clinical practice","volume":"18","author":"Barrera MV","year":"2008","journal-title":"Eur J Dermatol"},{"key":"e_1_2_4_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21655"},{"key":"e_1_2_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61000-4"},{"key":"e_1_2_4_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.087593"},{"key":"e_1_2_4_43_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.087411"},{"key":"e_1_2_4_44_2","first-page":"712","article-title":"Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2\u2003years of treatment with etanercept","volume":"33","author":"Mease PJ","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_4_45_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.073544"},{"key":"e_1_2_4_46_2","first-page":"1442","article-title":"Conventional systemic agents for psoriasis. A systematic review","volume":"33","author":"Strober BE","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_4_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06128.x"},{"key":"e_1_2_4_48_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05498.x"},{"key":"e_1_2_4_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08732.x"},{"key":"e_1_2_4_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08673.x"},{"key":"e_1_2_4_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2007.10.030"},{"key":"e_1_2_4_52_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0511"},{"key":"e_1_2_4_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.09.002"},{"key":"e_1_2_4_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08669.x"},{"key":"e_1_2_4_55_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630600967166"},{"key":"e_1_2_4_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2005.02626.x"},{"key":"e_1_2_4_57_2","first-page":"270","article-title":"Etanercept for the treatment of psoriasis: combination therapy with other modalities","volume":"3","author":"Strober BE","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_4_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.10.056"},{"key":"e_1_2_4_59_2","first-page":"1401","article-title":"Adalimumab in combination with methotrexate more effectively reduces the numbers of different inflammatory cell types in lesional psoriatic skin than does single treatment with adalimumab or methotrexate","volume":"159","author":"De Groot M","year":"2008","journal-title":"Br J Dermatol"},{"key":"e_1_2_4_60_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23141"},{"key":"e_1_2_4_61_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901283400401"},{"key":"e_1_2_4_62_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.043299"},{"key":"e_1_2_4_63_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11142"},{"key":"e_1_2_4_64_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21978"},{"key":"e_1_2_4_65_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21386"},{"key":"e_1_2_4_66_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21043"},{"key":"e_1_2_4_67_2","first-page":"S195","article-title":"Rheumatoid arthritis registries in Sweden","volume":"23","author":"Van Vollenhoven RF","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_4_68_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21568"},{"key":"e_1_2_4_69_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080791"},{"key":"e_1_2_4_70_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24632"},{"key":"e_1_2_4_71_2","article-title":"Drug\u2010specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti\u2010TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","author":"Dixon WG","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_4_72_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22768"},{"key":"e_1_2_4_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70227-5"},{"key":"e_1_2_4_74_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.146"},{"key":"e_1_2_4_75_2","article-title":"Association of Methotrexate and TNF antagonists with risk of infection outcomes including opportunistic infections in the CORRONA registry","author":"Greenberg JD","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_4_76_2","first-page":"175","article-title":"Infectious complications in patients with psoriasis and rheumatoid arthritis treated with antitumor necrosis factor agents and methotrexate","volume":"8","author":"Darabi K","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_4_77_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.4.7.953"},{"key":"e_1_2_4_78_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2008.03470.x"},{"key":"e_1_2_4_79_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.12.1627"},{"key":"e_1_2_4_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.041"},{"key":"e_1_2_4_81_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630500482928"},{"issue":"2","key":"e_1_2_4_82_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/738528792","article-title":"Acitretin suppression of squamous cell carcinoma: case report and literature review","volume":"14","author":"Lebwohl M","year":"2003","journal-title":"J Dermatol Treat"},{"key":"e_1_2_4_83_2","first-page":"245","article-title":"Utilization of narrow\u2010band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient\u2010reported outcomes","volume":"7","author":"Kircik L","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_4_84_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08926.x"},{"key":"e_1_2_4_85_2","volume-title":"Combined Treatment With Etanercept and Narrow Band UVB Phototherapy for Chronic Plaque Psoriasis","author":"De Simone C","year":"2007"},{"key":"e_1_2_4_86_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00147-004-0779-3"},{"key":"e_1_2_4_87_2","article-title":"Combination therapy with cyclosporin and etanercept in patients with psoriatic arthritis","author":"D\u2019Angelo S","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_4_88_2","unstructured":"Evaluation of Etanercept in Patients with Plaque Psoriasis After Stopping Ciclosporin Therapy[cited 14 September 2009]; Available from:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00581555?term=psoriasis+and+cyclosporin&rank=8."},{"key":"e_1_2_4_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.03.046"},{"key":"e_1_2_4_90_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094946"},{"key":"e_1_2_4_91_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"e_1_2_4_92_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"e_1_2_4_93_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.058339"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2010.03613.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2010.03613.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T08:49:06Z","timestamp":1697359746000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2010.03613.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,2]]},"references-count":92,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1468-3083.2010.03613.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2010.03613.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,2]]}}}